Lercanidipin Hydrochlorid Actavis (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels in vascular smooth muscle. This inhibition prevents calcium‑mediated contraction, leading to vasodilation of peripheral arteries. The resulting decrease in systemic vascular resistance lowers both systolic and diastolic blood pressure without significantly affecting heart contractility.

The appropriate dose of lercanidipine is determined by the prescribing healthcare professional based on the individual’s blood pressure, response to therapy, and any co‑existing medical conditions. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

The safety of lercanidipine in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both lercanidipine and amlodipine belong to the dihydropyridine class of calcium channel blockers and lower blood pressure through vasodilation. Lercanidipine has a longer half‑life and may provide smoother 24‑hour blood pressure control, while amlodipine is more widely used and has a well‑established safety profile. Choice depends on individual patient factors and clinician preference.

Lercanidipin Hydrochlorid Actavis should be stored at temperatures below 25 °C. Keep the tablets in the original packaging to protect them from moisture and light. Do not store in areas with high humidity or direct sunlight, and keep out of reach of children.

Lercanidipine is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their clinician and avoid crushing or chewing the tablet.

Serious adverse events, although rare, include severe hypotension, myocardial infarction, hepatic dysfunction, and allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience symptoms like fainting, chest pain, jaundice, or swelling of the face, lips, or tongue.

Lercanidipine is contraindicated in patients with known hypersensitivity to the drug or any component of the formulation. It should be used with caution in individuals with severe hepatic impairment, uncontrolled heart failure, or those taking strong CYP3A4 inhibitors. Pregnant or breastfeeding women should only use it if clearly indicated by a physician.